In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rethinking Diagnostics Contracts

Executive Summary

The nation's largest GPOs are rethinking the way they contract with diagnostics industry suppliers in light of new workstation consolidation coming on the market. Novation is considering combining immunoassay and clinical chemistry onto one contract; Premier is planning to hold a conference for members on the future of diagnostics and then a meeting of its laboratory task force to think of how to use new technologies.

You may also be interested in...



The State of Laboratory Unions

Hospital laboratory consolidation, underway for several years, is having mixed success as the market shifts. For suppliers, things are unlikely to settle down soon. Successful labs claim to be committed to a common vision and to swift action to institute painful changes. But other labs are stymied by politics, lack of top management support, and reluctance to make difficult decisions quickly. Manufacturers' expectations that consolidation would lead to standardization of equipment and a winner-take-all mentality are starting to come to pass. But the customer base continues to be in more flux than expected.

In Case You Missed It: China’s ‘Dual Circulation’ Policy, Fixing Safety Data ‘Overload,’ And More

We clean out your Thanksgiving inbox so you don't have to.

US FDA’s Comirnaty Review By The Numbers

A timeline of the review and development of the first COVID-19 vaccine to win BLA approval.

Topics

Related Companies

UsernamePublicRestriction

Register

IV001152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel